Executives at iBio (NASDAQ:IBIO) outlined the scientific and strategic rationale for a myostatin/activin A bispecific antibody program that the company believes could become a next-generation therapy ...
Earlier-line bispecific therapy leverages lower disease refractoriness to drive deeper, more durable responses than typically ...
Enara Bio, a pioneer in Dark Antigen(R) discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual ...
The US multi-center Phase 1/2 clinical trial of spevatamig (NCT05482893) is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced ...
The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major ...
Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific ...
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today ...
Akeso’s bispecific antibody improved overall survival in first-line patients with severe gastric cancer or gastroesophageal junction adenocarcinoma in a phase 3 trial, acing the primary endpoint. The ...
Bispecific inhibitor can combat a wide range of coronaviruses, including Paxlovid-resistant variants
A team of researchers have discovered a powerful bispecific inhibitor capable of combating all existing human-pathogenic coronaviruses, including those resistant to existing treatments like Paxlovid.
ABL Bio touts bispecific ADC gains, sets US trials for 206 and 209 Neoc Bio wins FDA clearance to begin phase 1 studies of ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that preclinical data from its IL ...
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results